Document is current
Any future updates will be listed below
-
Authors
Lechner, Matt https://orcid.org/0000-0002-7123-0773
Schartinger, Volker H. https://orcid.org/0000-0002-5887-7644
Steele, Christopher D.
Nei, Wen Long https://orcid.org/0000-0001-6027-1652
Ooft, Marc Lucas
Schreiber, Liesa-Marie
Pipinikas, Christodoulos P.
Chung, Grace Tin-Yun
Chan, Yuk Yu
Wu, Feng
To, Ka-Fai https://orcid.org/0000-0003-4919-3707
Tsang, Chi Man
Pearce, Wayne
Morelli, Daniele
Philpott, Martin
Masterson, Liam
Nibhani, Reshma
Wells, Graham
Bell, Christopher G. https://orcid.org/0000-0003-4601-1242
Koller, Julia
Delecluse, Susanne
Yip, Yim Ling https://orcid.org/0000-0003-1574-8022
Liu, Jacklyn
Forde, Cillian T. https://orcid.org/0000-0003-2017-2056
Forster, Martin D.
Jay, Amrita
Dudás, József
Krapp, Annika
Wan, Simon
Uprimny, Christian
Sprung, Susanne
Haybaeck, Johannes
Fenton, Tim R. https://orcid.org/0000-0002-4737-8233
Chester, Kerry
Thirlwell, Christina
Royle, Gary
Marafioti, Teresa
Gupta, Rajeev https://orcid.org/0000-0001-9573-0505
Indrasari, Sagung Rai
Herdini, Camelia
Slim, Mohd Afiq Mohd https://orcid.org/0000-0002-6835-1304
Indrawati, I.
Sutton, Liam
Fles, Renske
Tan, Bing
Yeong, Joe
Jain, Amit
Han, Shuting
Wang, Haitao https://orcid.org/0000-0001-6910-974X
Loke, Kelvin S. H.
He, Wan
Xu, Ruilian
Jin, Hongtao
Cheng, Zhiqiang
Howard, David
Hwang, Peter H.
Le, Quynh-Thu
Tay, Joshua K.
West, Robert B.
Tsao, Sai Wah
Meyer, Tim
Riechelmann, Herbert
Oppermann, Udo https://orcid.org/0000-0001-9984-5342
Delecluse, Henri-Jacques https://orcid.org/0000-0002-1744-6274
Willems, Stefan M.
Chua, Melvin L. K. https://orcid.org/0000-0002-1648-1473
Busson, Pierre https://orcid.org/0000-0003-1027-3400
Lo, Kwok Wai https://orcid.org/0000-0002-3488-6124
Wollmann, Guido
Pillay, Nischalan https://orcid.org/0000-0003-0579-4105
Vanhaesebroeck, Bart https://orcid.org/0000-0002-7074-3673
Lund, Valerie J.
- License Information
-
More Information
Article History
Received: 9 January 2020
Accepted: 17 November 2020
First Online: 5 January 2021
Competing interests
: B.V. is a consultant for Venthera (Palo Alto, US), iOnctura (Geneva, Switzerland) and Karus Therapeutics, Oxford, UK and has received speaker’s fees from Gilead (Foster City, US). T.Me. has acted as a consultant for Tarveda Therapeutics (Watertown, MA, US). G.W. serves as a scientific advisor to ViraTherapeutics and Boehringer Ingelheim. S.M. receives research grants from Pfizer, Bayer, MSD, AstraZeneca, Nextcure, Roche, BMS, Amgen and Lily. M.C. reports personal fees from Astellas, personal fees from Janssen, grants and personal fees from Ferring, personal fees from MSD Oncology, personal fees from Illumina, nonfinancial support from AstraZeneca, personal fees and nonfinancial support from Varian, nonfinancial support from GenomeDx Biosciences, nonfinancial support from Medlever, outside the submitted work. All other authors declare no competing interests.
